Hightide Therapeutics Inc (HK:2511)
:2511
Want to see HK:2511 full AI Analyst Report?
Top Page
Hightide Therapeutics Inc
(2511)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$4.00
▲(31.15% Upside)
Action:ReiteratedDate:05/07/26
The score is held back primarily by weak financial performance (no revenue, ongoing losses, and sustained cash burn), which outweighs the improved balance sheet. Technicals are a relative positive with price trading above key moving averages and a positive MACD, while valuation is neutral due to a negative P/E and no dividend yield data.
Positive Factors
Improved Balance Sheet
The shift to positive equity and a debt-to-equity near 0.41 indicates materially improved solvency versus prior years. This durable improvement reduces refinancing risk, gives management more strategic flexibility for R&D or partnerships, and lengthens runway absent immediate revenue.
Negative Factors
No Revenue
Absence of reported revenue means the company has not yet proven commercial viability and remains fully pre-revenue. Over the medium term this maintains dependence on financing, prevents operating leverage, and leaves future cash generation and profitability highly uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Balance Sheet
The shift to positive equity and a debt-to-equity near 0.41 indicates materially improved solvency versus prior years. This durable improvement reduces refinancing risk, gives management more strategic flexibility for R&D or partnerships, and lengthens runway absent immediate revenue.
Read all positive factors
Hightide Therapeutics Inc (2511) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.05B
Dividend YieldN/A
Average Volume (3M)1.41M
Price to Earnings (P/E)―
Beta (1Y)1.50
Revenue GrowthN/A
EPS Growth39.48%
CountryHK
Employees70
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.64
Shares Outstanding571,325,700
10 Day Avg. Volume641,080
30 Day Avg. Volume1,410,076
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.14
Price to Sales (P/S)0.00
P/FCF Ratio-7.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.80Price Target Upside90.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.56
Revenue Forecast (FY)HK$3.00B
Hightide Therapeutics Inc Business Overview & Revenue Model
Company Description
HighTide Therapeutics, Inc., an investment holding company, engages in the discovery, research and development, and commercialization of multifunctional therapies for the treatment of metabolic and digestive diseases with unmet medical needs. Its ...
How the Company Makes Money
null...
Hightide Therapeutics Inc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -2.02M | -1.30M | -1.56M |
| EBITDA | -196.37K | -217.78M | -444.22K | -1.04B | -229.56M | -131.80M |
| Net Income | -291.16K | -238.63M | -381.79K | -1.04B | -190.24M | -221.15M |
Balance Sheet | ||||||
| Total Assets | 528.48M | 551.58M | 559.93M | 795.04M | 855.82M | 777.23M |
| Cash, Cash Equivalents and Short-Term Investments | 467.01M | 502.94M | 490.52M | 735.70M | 828.33M | 763.91M |
| Total Debt | 99.47M | 126.92M | 77.91M | 16.43M | 1.27B | 1.01B |
| Total Liabilities | 160.66M | 186.75M | 135.76M | 92.26M | 1.33B | 1.05B |
| Stockholders Equity | 315.51M | 307.14M | 424.17M | 702.77M | -470.53M | -271.77M |
Cash Flow | ||||||
| Free Cash Flow | -112.44M | -166.98M | -299.46M | -368.56M | -172.90M | -90.12M |
| Operating Cash Flow | -107.85M | -166.91M | -294.81M | -367.67M | -172.71M | -88.40M |
| Investing Cash Flow | 65.21M | -102.90M | -89.72M | 321.64M | -415.66M | 1.59M |
| Financing Cash Flow | 60.92M | 199.72M | 54.79M | 399.46M | 46.03M | 493.98M |
Hightide Therapeutics Inc Technical Analysis
Positive
3.05
Price Trends
2.89
Positive
2.86
Positive
3.17
Positive
Market Momentum
0.23
Negative
68.37
Neutral
83.34
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2511, the sentiment is Positive. The current price of 3.05 is below the 20-day moving average (MA) of 3.32, above the 50-day MA of 2.89, and below the 200-day MA of 3.17, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 68.37 is Neutral, neither overbought nor oversold. The STOCH value of 83.34 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2511.
Hightide Therapeutics Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$2.05B | -2.75 | -39.41% | ― | ― | 39.48% | |
49 Neutral | HK$1.86B | 8.68 | 43.89% | ― | 150.60% | ― | |
44 Neutral | HK$1.94B | -7.60 | -27.70% | ― | -100.00% | 50.29% | |
43 Neutral | HK$937.62M | -3.97 | -27.44% | ― | -33.80% | 31.29% | |
42 Neutral | HK$1.68B | -3.75 | -41.22% | ― | 20.92% | 27.49% | |
41 Neutral | HK$1.28B | ― | 9.41% | ― | -41.19% | ― |
* Healthcare Sector Average
HK:2511
Hightide Therapeutics Inc
4.02
1.69
72.53%
HK:1228
CANbridge Pharmaceuticals Inc.
2.15
2.01
1435.71%
HK:2181
Mabpharm Limited
0.45
0.01
2.27%
HK:3681
SinoMab Bioscience Ltd.
1.41
0.12
9.30%
HK:6628
Transcenta Holding Limited
2.12
0.92
76.67%
HK:2487
Cutia Therapeutics
4.60
-2.05
-30.83%
Hightide Therapeutics Inc Corporate Events
HighTide Therapeutics Strengthens Board With Appointment of Veteran Audit Chairman
May 4, 2026
HighTide Therapeutics has appointed veteran finance and tax expert Chen Mingyu as an independent non-executive director, chairman of the audit committee and member of the remuneration committee, effective May 4, 2026. Chen brings more than 35 year...
HighTide Therapeutics Details Board Composition and Committee Roles
May 4, 2026
HighTide Therapeutics Inc. announced the current composition of its board of directors, detailing the roles of executive, non-executive, and independent non-executive directors, including Chairwoman and CEO Dr. Liu Liping. The company also disclos...
HighTide Therapeutics Grants HK$15 Million Connected-Party Loan to Founder-CEO
Apr 27, 2026
HighTide Therapeutics has entered into a connected transaction by signing a loan agreement to provide up to HK$15 million in unsecured financing to its founder, chairwoman and CEO, Dr. Liu Liping, primarily for her tax compliance needs. The loan c...
HighTide Therapeutics Highlights HTD1801’s Potential as Foundational CKM Therapy in 2025 Results
Mar 30, 2026
HighTide Therapeutics reported its audited consolidated annual results for the year ended December 31, 2025, and detailed a change in the use of proceeds, underscoring its continued focus on advancing HTD1801 as its core asset. The company highlig...
HighTide positions HTD1801 as potential foundational therapy for CKM diseases
Mar 27, 2026
HighTide reported that its core product HTD1801 is the only clinical-stage compound addressing residual risks in CKM-related diseases through the dual mechanisms of AMPK activation and NLRP3 inflammasome inhibition. The company highlights extensiv...
HighTide Therapeutics Sets March 27 Board Meeting to Approve 2025 Annual Results
Mar 13, 2026
HighTide Therapeutics, Inc. has scheduled a board meeting for March 27, 2026, to review and approve the audited annual results for the financial year ended December 31, 2025, and to authorize their publication. The meeting will also address other ...
HighTide’s First NDA for Diabetes Drug HTD1801 Accepted by China’s NMPA
Mar 10, 2026
HighTide Therapeutics said China’s National Medical Products Administration has accepted its first New Drug Application for HTD1801 to treat Type 2 diabetes, a key step toward commercializing the company’s lead asset. The filing unders...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.